Massachusetts Federal district court ruled that Janssen Biotech, Inc.’s US Patent No. 6,284,471 for Remicade (infliximab) is invalid. Janssen will appeal to the CAFC.
Janssen’s Remicade Patent Invalid According to Massachusetts Court
Leave a reply
